Clinical trial
A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG…
NCT00323505 · Royal Marsden NHS Foundation Trust, Other · Completed
Key facts
| NCT number | NCT00323505 |
|---|---|
| Title | A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma |
| Lead sponsor | Royal Marsden NHS Foundation Trust, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Pegylated Interferon, Interferon-alpha2a |
| Start date | Mar 1, 2001 |
| Completion | Dec 1, 2004 |
| First posted | May 9, 2006 |
| Last update posted | May 9, 2006 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: